Bora Pharmaceuticals Co., Ltd. (BORAY)

OTCMKTS · Delayed Price · Currency is USD

2.210

0.00 (0.00%)

At close: May 29, 2026

Market Cap	1.41B -41.9%
Revenue (ttm)	579.61M -2.7%
Net Income	50.28M -64.6%
EPS	0.27 -73.1%
Shares Out	n/a
PE Ratio	28.13
Forward PE	11.02
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,000
Open	2.210
Previous Close	n/a
Day's Range	2.210 - 2.210
52-Week Range	2.210 - 5.000
Beta	0.57
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 10, 2026

About Bora Pharmaceuticals

Bora Pharmaceuticals Co., Ltd. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services and technical services for the development of pharmaceutical products. In addition, it provides Western pharmaceuticals, including central nervous system medications, antibioti... [Read more]

Industry Pharmaceutical Preparations

Founded 2007

Country Taiwan

Stock Exchange OTCMKTS

Ticker Symbol BORAY

Financial Performance

In 2025, Bora Pharmaceuticals's revenue was 19.01 billion, an increase of 9.11% compared to the previous year's 17.43 billion. Earnings were 2.98 billion, a decrease of -22.61%.

Financial numbers in TWD Financial Statements

News

Bora Pharmaceuticals Earnings Call Transcript: Q1 2026

Q1 2026 saw a sequential revenue decline due to scheduled maintenance and generics headwinds, but March rebounded and strong order backlog supports a positive outlook. Two major acquisitions—MacroGenics CDMO and Weider Global Nutrition—are set to drive growth and diversify revenue.

21 days ago - Transcripts

Bora Pharmaceuticals Slides: Q1 2026

Bora Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.

21 days ago - Filings

Bora Pharmaceuticals Transcript: Life Sciences Virtual Investor Forum

FY2025 saw record revenues, major CDMO contract wins, and expansion into biologics, with specialty pharma now 45% of sales. Investments in U.S. and Taiwan facilities, AI, and ESG initiatives position the company for strong growth in CDMO, biologics, and rare disease markets in 2026.

2 months ago - Transcripts

Bora Pharmaceuticals Slides: Q4 2025

Bora Pharmaceuticals has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 10, 2026.

3 months ago - Filings

Bora Pharmaceuticals Quarterly report: Q4 2025

Bora Pharmaceuticals has published its Q4 2025 quarterly earnings report on March 10, 2026.

3 months ago - Filings

Bora Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Significant expansion and operational improvements drove 2025 revenue to $634 million, with a 700% market cap increase since 2017. Strategic U.S. investments, a focus on high-value generics and rare diseases, and strong ESG performance position the company for continued growth.

4 months ago - Transcripts

Bora Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Bora Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on January 15, 2026.

4 months ago - Filings

Bora Pharmaceuticals Earnings Call Transcript: Q3 2025

Record CDMO and specialty pharma growth drove a 15% year-over-year revenue increase and improved margins, despite ongoing integration and external headwinds. Strategic acquisitions, capacity expansions, and a focus on high-value products position the business for continued growth into 2026.

7 months ago - Transcripts